
    
      This is a multicenter, open-label, prospective study of cilostazol use to prevention of
      recurrence in patients with cerebral infarction.

      Qualified patients will be treated with cilostazol by physician's assessment. This study will
      be continued for 4 years. More than 600 patients for 4 years.
    
  